pharma · Diabetes Mellitus · Hemophilia A
Takeda is a pharma organization headquartered in Cambridge, USA. Primary therapeutic focus areas include Diabetes Mellitus, Hemophilia A, Crohn's Disease, Hypertension, Type 2 Diabetes Mellitus. NovaPharmaNews links 1179
Phase 3 · small molecule · Pouchitis
Vedolizumab (ENTYVIO) is an injectable small-molecule therapeutic developed by Takeda Pharmaceuticals for the treatment of pouchitis, an inflammatory complication affecting patients with ileal pouch-anal anastomosis (IPAA) surgery. The program is currently in Phase 3 clinical development under internal code Vedolizumab
Internal code Vedolizumab-3041
Vedolizumab (ENTYVIO) is an injectable small-molecule therapeutic developed by Takeda Pharmaceuticals for the treatment of pouchitis, an inflammatory complication affecting patients with ileal pouch-anal anastomosis (IPAA) surgery. The program is currently in Phase 3 clinical development under internal code Vedolizumab-3041. Vedolizumab is already approved in multiple markets including the United States, European Union, and Australia for other indications, with regulatory status in these regions established through applications BLA125476, BLA761133, and BLA761359 (US), EMEA/H/C/002782 (EU, authorized 15 January 2026), and multiple PBS codes in Australia (first listed 1 August 2015, with subsequent listings through October 2024). The Phase 3 program for pouchitis (NCT06443502) represents a label expansion strategy for an established therapeutic. The latest program milestone was recorded on 19 September 2025, though specific milestone details are not yet disclosed. Takeda's development approach leverages the existing safety and efficacy database of vedolizumab in related inflammatory bowel conditions to address the unmet medical need in pouchitis management.
Pouchitis represents a significant unmet medical need in gastroenterology, affecting a subset of patients who have undergone restorative proctocolectomy with IPAA construction, typically performed for ulcerative colitis or familial adenomatous polyposis. The condition causes inflammation of the surgically created pouch and can severely impact quality of life, with limited pharmacological treatment options currently available. The competitive landscape for pouchitis treatment remains fragmented, with various antimicrobial agents (rifaximin, vancomycin, metronidazole, ciprofloxacin, amoxicillin-clavulanate) and emerging biologics being investigated. Vedolizumab's mechanism as an established integrin antagonist with proven efficacy in ulcerative colitis and Crohn's disease provides a mechanistically rational approach to pouchitis inflammation. Market relevance is substantial given the chronic nature of pouchitis and the need for effective maintenance therapies. Takeda's strategy to expand vedolizumab's label into pouchitis leverages the drug's established safety profile and manufacturing infrastructure, positioning it as a potential standard-of-care option. The patient population, while specialized, represents a high-value segment due to the severity of disease and limited alternatives. Regulatory approval in pouchitis could establish vedolizumab as a foundational therapy in this indication and extend the commercial lifecycle of ENTYVIO.
Vedolizumab (ENTYVIO) is a small-molecule therapeutic administered via injection. The drug is manufactured and sponsored by Takeda Pharmaceuticals. While the mechanism of action and specific molecular target are not yet disclosed in available documentation, vedolizumab is established in clinical practice for inflammatory bowel disease indications. The drug is delivered by injection route of administration.
Prevalence: Point prevalence: 1-5 / 10 000 (Europe) — source: Orphanet, validated.
Acute inflammation in the intestinal mucosa of the continent ileal reservoir (or pouch) in patients who have undergone ileostomy and restorative proctocolectomy (proctocolectomy, restorative).
ClinicalTrials.gov lists 45 registered studies for Pouchitis (AACT aggregate).
Phase breakdown: NA (16), PHASE2 (10), PHASE3 (6), PHASE4 (5), PHASE1/PHASE2 (3), EARLY_PHASE1 (2), PHASE1 (2), PHASE2/PHASE3 (1)
Common investigational therapies:
Disease data sourced from MONDO Disease Ontology (MONDO:0005312), Orphanet — pouchitis, NCT00061282, NCT00293553, NCT00583076, NCT00583531, NCT01202396, AACT (ClinicalTrials.gov aggregate), ClinicalTrials.gov, Open Targets Platform (CC BY 4.0).
First Australian approval
Vedolizumab approved in Australia (PBS code 10384M) by Takeda Pharmaceuticals Australia Pty. Ltd.
Australian label expansion
Additional PBS codes assigned (10390W, 10398G, 10415E) indicating label expansion or formulation changes in Australia.
Australian regulatory update
Further PBS codes assigned (12620F, 12638E, 12639F, 12644L, 12647P, 12654B) reflecting ongoing regulatory activity.
European Union authorization
Vedolizumab authorized in the European Union (EMEA/H/C/002782) under Takeda Pharma A/S as marketing authorization holder.
Phase 3 pouchitis program milestone
Latest milestone recorded for Vedolizumab-3041 Phase 3 program (NCT06443502); specific details not yet disclosed.
The pouchitis treatment landscape includes multiple competing approaches across different development stages. Antimicrobial agents dominate current clinical practice, with rifaximin, vancomycin, metronidazole, ciprofloxacin, and amoxicillin-clavulanate combinations representing first-line and adjunctive therapies. Within Takeda's own portfolio, vedolizumab placebo serves as the control comparator in clinical trials, while a combination approach incorporating rifaximin, vancomycin, ENTYVIO 300 mg formulation, amoxicillin-clavulanate, ciprofloxacin, and metronidazole is in Phase 3 development, suggesting a potential multi-modal strategy. Lacuna Pharma Pty Ltd is advancing metronidazole, fosfomycin, and molgramostim combinations in Phase 2, targeting the antimicrobial and immunomodulatory space. MAIA Biotechnology is pursuing etrasimod (a small-molecule S1P receptor modulator) in Phase 2 and exploring fecal microbiota transplantation (FMT) in Phase 1, representing mechanistically distinct approaches to pouchitis inflammation. Vedolizumab's competitive advantage derives from its established safety profile in inflammatory bowel disease, defined mechanism of action targeting integrin-mediated inflammation, and regulatory precedent across multiple markets. The competitive field remains fragmented with no clear market leader, creating opportunity for vedolizumab to establish itself as a biologically-targeted option distinct from antimicrobial-first strategies.
| Therapy | Company | Mechanism | Status |
|---|---|---|---|
| Vedolizumab Placebo | Takeda | small_molecule | approved |
| RIFAXIMIN , VANCOMYCIN , Entyvio 300 mg powder for concentrate for solution for infusion, AMOXICILLIN AND BETA-LACTAMASE INHIBITOR , CIPROFLOXACIN , METRONIDAZOLE | Takeda | small_molecule | phase_3 |
| METRONIDAZOLE, FOSFOMYCIN, MOLGRAMOSTIM | Lacuna Pharma Pty Ltd | small_molecule | phase_2 |
| etrasimod | MAIA Biotechnology | small_molecule | phase_2 |
| Fecal Microbiota Transplant (FMT) | MAIA Biotechnology | small_molecule | phase_1 |
| VEDOLIZUMAB | — | Integrin alpha-4/beta-7 inhibitor | Phase 3 |
| USTEKINUMAB | — | Interleukin-23 inhibitor | Phase 3 |
| ALICAFORSEN | — | Intercellular adhesion molecule-1 mRNA 3'UTR antisense inhibitor | Phase 3 |
| TOFACITINIB | — | Janus Kinase (JAK) inhibitor | Phase 2 |
| LIRAGLUTIDE | — | Glucagon-like peptide 1 receptor agonist | Phase 2 |
| SARGRAMOSTIM | — | Granulocyte-macrophage colony-stimulating factor receptor agonist | Phase 1 |
Additional associated therapies sourced from Open Targets Platform (CC0), linked to NovaPharmaNews drug profiles where matched.
United States: Vedolizumab (ENTYVIO) is approved by the FDA under three biologics license applications: BLA125476, BLA761133, and BLA761359. The pouchitis indication (Phase 3, NCT06443502) represents a label expansion pathway not yet concluded.
European Union: Vedolizumab received European Commission authorization on 15 January 2026 under EMEA/H/C/002782, with Takeda Pharma A/S as the marketing authorization holder. Pouchitis indication approval status not yet disclosed.
Australia: Vedolizumab is approved and listed on the Pharmaceutical Benefits Scheme (PBS) with multiple codes: 10384M (initial listing, 1 August 2015), 10390W, 10398G, 10415E (21 September 2021), and 12620F, 12638E, 12639F, 12644L, 12647P, 12654F (1 October 2024). Sponsor: Takeda Pharmaceuticals Australia Pty. Ltd.
China: Vedolizumab is in clinical trials in China (NCT07398586), with regulatory approval status not yet disclosed.
Japan (PMDA): Regulatory status not yet disclosed.
Vedolizumab (ENTYVIO) is approved for inflammatory bowel disease indications in the United States, European Union, and Australia. A Phase 3 program is currently evaluating vedolizumab for the treatment of pouchitis, an inflammatory condition affecting patients with surgically created pouches.
Vedolizumab is not yet approved for pouchitis. The drug is currently in Phase 3 clinical development for this indication (NCT06443502), with the latest milestone recorded on 19 September 2025. Regulatory approval status and timeline are not yet disclosed.
The specific mechanism of action for vedolizumab is not yet disclosed in available documentation. However, vedolizumab is established in clinical practice as a therapeutic for inflammatory bowel disease, suggesting an anti-inflammatory mechanism targeting intestinal inflammation.
Vedolizumab is manufactured and sponsored by Takeda Pharmaceuticals. In Australia, the sponsor is listed as Takeda Pharmaceuticals Australia Pty. Ltd., and in Europe, Takeda Pharma A/S holds the marketing authorization.
The brand name is ENTYVIO, marketed by Takeda Pharmaceuticals globally.
Vedolizumab is administered via injection. The specific injection route (intravenous, subcutaneous) and dosing frequency are not yet disclosed in the available facts.
NCT06443502 is the Phase 3 clinical trial evaluating vedolizumab for pouchitis treatment. The trial is active as of 19 September 2025, though detailed trial design, enrollment, and endpoints are not yet disclosed.
Vedolizumab was first approved in Australia on 1 August 2015 (PBS code 10384M). It is also approved in the United States (BLA125476, BLA761133, BLA761359) and the European Union (authorized 15 January 2026, EMEA/H/C/002782).
Competing treatments include antimicrobial agents (rifaximin, vancomycin, metronidazole, ciprofloxacin, amoxicillin-clavulanate), etrasimod (MAIA Biotechnology, Phase 2), fecal microbiota transplantation (MAIA Biotechnology, Phase 1), and various antimicrobial combinations (Lacuna Pharma, Phase 2).
Yes, vedolizumab received European Commission authorization on 15 January 2026 under EMEA/H/C/002782. However, approval for the pouchitis indication is not yet disclosed.
Vedolizumab is in clinical trials in China (NCT07398586), but regulatory approval status in China is not yet disclosed.
Vedolizumab is in Phase 3 clinical development for pouchitis (program code Vedolizumab-3041, NCT06443502). A milestone was recorded on 19 September 2025, but specific details are not yet disclosed.
Pouchitis is an inflammatory condition affecting patients who have undergone restorative proctocolectomy with ileal pouch-anal anastomosis (IPAA) surgery, typically performed for ulcerative colitis or familial adenomatous polyposis. It causes inflammation of the surgically created pouch and can significantly impact quality of life.
No partnership is disclosed for the vedolizumab pouchitis program. Takeda is developing the program independently.
Projected peak sales for vedolizumab are not yet disclosed.
Vedolizumab is classified as a small-molecule therapeutic administered via injection.
Vedolizumab → Drug → Target → Indication → Company → Trials → Competitors
Strategic Implications: Takeda's Phase 3 expansion of vedolizumab into pouchitis represents a focused label extension strategy leveraging an established therapeutic asset. The program builds on vedolizumab's proven efficacy in related inflammatory bowel conditions and existing regulatory precedent across major markets, reducing development risk compared to de novo indications. The 19 September 2025 milestone suggests active trial progression, though specific outcomes remain undisclosed.
Competitive Implications: Vedolizumab's entry into pouchitis with a biologically-targeted mechanism differentiates it from the current antimicrobial-dominated treatment paradigm. The competitive field remains fragmented with no established standard of care, creating opportunity for vedolizumab to establish market leadership. However, MAIA Biotechnology's etrasimod (Phase 2) and FMT (Phase 1) programs represent emerging mechanistic alternatives. Lacuna Pharma's Phase 2 program targeting antimicrobial combinations may compete on cost and accessibility.
Future Catalysts: Phase 3 data readout for NCT06443502 represents the critical near-term catalyst. Regulatory submissions to FDA, EMA, and other agencies would follow positive efficacy and safety data. Potential label expansion approvals could occur 12-24 months post-data readout depending on regulatory pathway and priority review status. International expansion into China (NCT07398586) and other markets would extend commercial opportunity.
Expected Milestones: Phase 3 completion and data presentation; regulatory submissions (FDA, EMA); approval decisions; label expansion in existing markets; potential combination therapy studies with antimicrobial agents.
Concise, citable answers optimized for AI answer engines.
Intelligence compiled from public regulatory and clinical sources (FDA, EMA, ClinicalTrials.gov and company disclosures). Figures may be editorial or analyst estimates; verify against primary sources before relying on them.